Article Abstract

How to optimize the treatment strategy for patients with EGFR-mutant stage IA lung adenocarcinoma: an international multidisciplinary team

Authors: Yalei Zhang, Jianfei Shen, Charles B. Simone II, Federico Cappuzzo, Kwun M. Fong, Rafael Rosell, Joe Y. Chang, Luca Ampollini, J. Isabelle Choi, Jianxing He, Tao Jiang, Written on behalf of AME Lung Cancer Cooperative Group


Although most patients with stage I non-small cell lung cancer (NSCLC) can achieve long-term survival, some still remain at high risk of relapse (1-3). The excellent outcomes and increasing use of stereotactic ablative radiotherapy (SABR) for stage I NSCLC has recently posed a challenge to surgery (4,5). Nevertheless, lobectomy with mediastinal lymph node dissection or sampling has remained the standard of care for operable, stage I NSCLC.